ScholarIQanswers from OpenAlex & ORCID
Brian Dougherty
ResearcherPublications, citations & collaboration network
Brian Dougherty is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Brian Dougherty have?
ScholarIQindexed works
Brian Dougherty has 226 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Brian Dougherty have?
ScholarIQcitation count
Brian Dougherty has 31,155 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Brian Dougherty?
ScholarIQh-index
Brian Dougherty has an h-index of 46 in OpenAlex.
What is the i10-index of Brian Dougherty?
ScholarIQi10-index
Brian Dougherty has an i10-index of 68 in OpenAlex.
What is the ORCID of Brian Dougherty?
ScholarIQorcid
The ORCID for Brian Dougherty is on the source record.
What is the OpenAlex record for Brian Dougherty?
ScholarIQopenalex
The OpenAlex for Brian Dougherty is on the source record.
What are the most-cited papers on Brian Dougherty?
ScholarIQmost cited works
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
Kenneth S. Thress, Cloud P. Paweletz, Enriqueta Felip, Byoung Chul Cho, Daniel Stetson, Brian Dougherty, Zhongwu Lai, Aleksandra Markovets, Ana Vivancos, Yanan Kuang, Dalia Ercan, Sarah E Matthews, Mireille Cantarini, J. Carl Barrett, Pasi A. Jänne, Geoffrey R. Oxnard
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial
Amit M. Oza, David Cibula, Ana Oaknin Benzaquen, Christopher Poole, Ron H.J. Mathijssen, Gabe S. Sonke, Nicoletta Colombo, Jiří Špaček, Peter Vuylsteke, Holger W. Hirte, Sven Mahner, Marie Plante, Barbara Schmalfeldt, Helen Mackay, Jacqui Rowbottom, Elizabeth Lowe, Brian Dougherty, J. Carl Barrett, Michael Friedländer
Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial
Peter Schmid, Jacinta Abraham, Stephen Chan, Duncan Wheatley, Adrian Murray Brunt, Gia Nemsadze, Richard D. Baird, Yeon Hee Park, Peter S Hall, Timothy Perren, Robert C. Stein, László Mangel, Jean-Marc Ferrero, Melissa Phillips, John Conibear, Javier Cortés, Andrew Foxley, Elza C. de Bruin, Robert McEwen, Daniel Stetson, Brian Dougherty, Shah‐Jalal Sarker, Aaron Prendergast, Max McLaughlin-Callan, Matthew Burgess, Cheryl Lawrence, Hayley Cartwright, Kelly Mousa, Nicholas C. Turner
Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models
Catherine A. Eberlein, Daniel Stetson, Aleksandra Markovets, Katherine Al-Kadhimi, Zhongwu Lai, Paul R. Fisher, Catherine B. Meador, Paula J. Spitzler, Eiki Ichihara, Sarah J. Ross, Miika Ahdesmäki, Ambar Ahmed, Laura E. Ratcliffe, Elizabeth L. Christey O'Brien, Claire H. Barnes, H. Shelton Brown, Paul D. Smith, Jonathan R. Dry, Garry Beran, Kenneth S. Thress, Brian Dougherty, William Pao, Darren A.E. Cross